Seropositivity and Titers of Anti-Smooth Muscle Actin Antibody Are Associated with Relapse of Type 1 Autoimmune Hepatitis

Background: It is important to avoid relapse in autoimmune hepatitis (AIH) because repeated multiple relapses have been associated with a worse prognosis. However, risk factors for relapse before initiation of treatment are not fully understood. The aim of this study was to find predictive markers for relapse of type 1 AIH.

Material/Methods: We reviewed the records of 53 patients diagnosed with type 1 AIH based on the revised scoring system proposed by the International Autoimmune Hepatitis Group (IAIHG) between 2009 and 2014 at 4 hospitals belonging to the Saga Study Group of Liver Diseases (SASLD). We analyzed the differences in background characteristics between patients with or without relapse.

Results: All patients achieved remission after treatment, and 9 (17%) subsequently relapsed. The relapsed patients were significantly younger and had a higher positive rate of anti-smooth muscle antibody (ASMA) than the non-relapsed patients (100% vs. 25%, P=0.0012). Moreover, relapse rate increased with titer of ASMA, while titer of antinuclear antibody was not associated with relapse rate.

Conclusions: ASMA is a useful predictive marker for relapse of type 1 AIH during or after withdrawal of medical therapy. More careful attention should be paid to immunosuppressive therapy in patients with high titers of ASMA.

MeSH Keywords: Autoantibodies • Hepatitis, Autoimmune • Recurrence

Full-text PDF: https://www.medscimonit.com/abstract/index/idArt/902576

Indexed in: [Current Contents/Clinical Medicine] [SCI Expanded] [ISI Alerting System] [ISI Journals Master List] [Index Medicus/MEDLINE] [EMBASE/Excerpta Medica] [Chemical Abstracts/CAS] [Index Copernicus]

This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
Background

Autoimmune hepatitis (AIH) is a chronic inflammatory liver disease of unknown etiology that typically affects women, and is characterized by elevated liver enzymes and serum immunoglobulins, and autoantibodies. Some studies have reported the importance of achieving normalization of alanine aminotransferase (ALT) levels and a good response to immunosuppressive therapy to attain good prognosis [1,2]. Most patients attain normalization of ALT within 6 months after the introduction of immunosuppressive therapy [3]; therefore, the prognosis of AIH is generally good. However, it has been reported that multiple relapses, compared with single relapse or sustained remission, are associated with a worse prognosis. Patients who had relapsed repeatedly and required retreatment have high risk of several steroid-related complications, including diabetes, stomach ulcer, and osteoporosis, as well as high risk of developing cirrhosis and hepatic death or need for liver transplantation [4,5].

A previous study showed that the duration and the tapering rate of corticosteroid administration until ALT normalization were associated with relapse [6]. However, there are, in fact, some patients who relapse in spite of continuous and sufficient immunosuppressive therapy. Although another study demonstrated that patient characteristics such as age, ALT, or IgG level were related to relapse, it is still unclear whether this is true [7]. Accordingly, finding factors associated with relapse is very important to management of AIH patients and would help improve their outcomes.

AIH is classified into types 1 and 2, based on autoantibody profile. Anti-smooth muscle antibody (ASMA) and antinuclear antibody (ANA) have been used to define type 1 AIH, and antibodies to liver–kidney microsome (anti-LKM) type 1 have been used to define type 2 AIH [8]. According to a Japanese nationwide survey, approximately 90% of AIH cases were positive for ANA, and ASMA was seen in 42.5% [3], whereas anti-LKM1 is rarely found in Japan [9]. Some recent studies have demonstrated that these autoantibodies might be associated with disease activity of AIH.

Therefore, the aim of this study was to find risk factors for relapse of type 1 AIH, including autoantibody status, disease severity, mode of disease onset, and liver histology before treatment.

Material and Methods

Study population

We reviewed the records of patients diagnosed with type 1 AIH between 2009 and 2014 at 4 hospitals associated with the Saga Study Group of Liver Diseases (SASLD). Seventy-six patients were diagnosed with AIH based on the revised scoring system proposed by the IAIHG [10] and the profile of autoantibodies. Patients with hepatic failure at diagnosis, hepatitis B or C virus infection, evidence of alcohol- or drug-induced liver injury, or incomplete medical records were excluded from this study. Finally, we enrolled 53 patients and analyzed their clinical and laboratory data retrospectively. All the patients satisfied the IAIHG diagnostic criteria for probable or definite AIH. The median observation period was 46.2 months. For eligible patients, the following clinical characteristics were examined: sex, age, body mass index (BMI), blood counts, biochemical tests, IgG levels, autoantibodies (including ANA and ASMA), concomitant autoimmune diseases, disease severity, type of disease presentation, treatment method, and liver histology. The Institutional Review Board or Ethics Committee of each institution approved the study protocol.

Remission was defined as improvement of serum ALT levels within the upper limit of normal (ULN) after medical treatment. Relapse was defined as serum ALT levels \( > 2 \times \text{ULN} \) after remission [11]. Acute AIH was defined as acute presentation of symptoms with serum total bilirubin levels \( > 5 \text{mg/dL} \) and/or serum ALT levels \( > 10 \times \text{ULN} \), and no history of liver disease [12]. Disease severity was classified as described previously [13].

Detection of ANA and ASMA was carried out by indirect immunofluorescence using HEp-2 cells or frozen sections of rat kidney. A serum titer of 1:40 or more was defined as positive for ANA and ASMA.

All but 1 case underwent liver biopsy to evaluate pathological characteristics before or just after initiation of treatment. Percutaneous liver biopsy was performed with a 16-gauge needle using an ultrasound-guided technique. Fibrotic staging ranged from 0 to 4 [14].

Statistical analysis

Differences in patient characteristics and laboratory data between those with and without relapse were assessed using the \( \chi^2 \) test for categorical data and \( t \) test for continuous variables. \( P < 0.05 \) was considered statistically significant. Statistical analyses were conducted with R version 3.0.1 (The R Foundation for Statistical Computing, Vienna, Austria).

Results

All 53 patients achieved remission once after initial treatment, and 9 (17%) subsequently relapsed. Table 1 shows the differences in clinical characteristics at the time of diagnosis according to patients with/without relapse.
There were no significant differences between the 2 groups with respect to sex, liver function, ANA-positive rate, IgG levels, type of disease presentation, and grade of severity. However, the relapsed group was significantly younger ($P=0.0028$, 50.7 years vs. 63.5 years) and had a significantly higher ASMA-positive rate ($P=0.0012$, 100% vs. 25%) in the 34 patients measured. All 6 of the relapsed patients were positive for ASMA, whereas only 7 of 28 (25%) were positive for ASMA in the non-relapsed group.

Nine patients had a concomitant autoimmune disease: 3 with primary biliary cirrhosis, 2 each with hypothyroidism or rheumatoid arthritis, and 1 each with hyperthyroidism, systemic lupus erythematosus, or systemic sclerosis. The rate of comorbidity

### Table 1. Comparison of patients characteristics between with and without relapse.

| Characteristic                  | Relapse (n=9) | Non-relapse (n=44) | P   |
|--------------------------------|---------------|--------------------|-----|
| Age (years)                    | 50.7±13.0     | 63.5±10.8          | 0.0028|
| Female                         | 9 (100)       | 38 (86.4)          | 0.2394|
| Body mass index (kg/m²)        | 20.6±7.6      | 22.6±3.8           | 0.2378|
| Platelet ($10^4$/mm³)          | 17.4±6.2      | 18.1±6.6           | 0.7546|
| Albumin (g/dL)                 | 3.9±0.4       | 3.7±0.6            | 0.3361|
| Total bilirubin (mg/dL)        | 4.0±7.4       | 3.6±4.7            | 0.8243|
| AST (IU/L)                     | 383±424.9     | 402±463.7          | 0.9123|
| ALT (IU/L)                     | 563.2±570.4   | 430.7±495.1        | 0.4787|
| γ-glutamyltranspeptidase (IU/L)| 146.4±114.1   | 207.9±158.5        | 0.2757|
| Alkaline phosphatase (IU/L)    | 478.3±255.4   | 488.8±225.6        | 0.9020|
| Prothrombin activity (%)       | 84.7±19.5     | 82.2±17.8          | 0.7100|
| IgG (mg/dL)                    | 2044.1±574.9  | 2140.1±762.4       | 0.7230|
| ANA positive                   | 9 (100)       | 40 (90.9)          | 0.0851|
| ASMA positive*                 | 6/6 (100)     | 7/28 (25)          | 0.0012|
| HLA-DR4 positive**             | 8/9 (88.9)    | 17/29 (58.6)       | 0.0945|
| Revised IAIHG score            | 15.4±2.3      | 14.7±2.8           | 0.4436|
| Definite diagnosis             | 5 (55.6)      | 19 (42.2)          | 0.4968|
| Severity (%)                   | 1 (11.1)      | 3 (6.8)            | 0.6569|
| Liver histology                |               |                    |      |
| Fibrosis stage F3 or F4        | 0 (0)         | 10 (22.7)          | 0.0779|
| Acute onset                    | 2 (22.2)      | 8 (18.2)           | 0.7777|
| Concomitant autoimmune disease | 0 (0)         | 9 (20.5)           | 0.1365|
| Treatment                      |               |                    |      |
| With steroid (predonisolone)    | 9 (100)       | 36 (81.8)          | 0.1651|
| Initial dose (mg)              | 39.3±6.1      | 34.0±10.1          | 0.1958|
| Maintenance dose (mg)          | 3.2±4.0       | 4.0±3.5            | 0.6137|
| Withdrawal                     | 3 (42.9)      | 6 (20.0)           | 0.2044|
| Reduction rate until ALT normalization (mg/week) | 1.5±1.2 | 1.4±1.6 | 0.8807|
| Duration to remission (weeks)  | 3.7±3.5       | 3.4±3.8            | 0.8216|

Results are expressed as the mean ± standard deviation or number (%). Statistical differences were analysed by t-test or χ² test.

AST – aspartate aminotransferase; ALT – alanine aminotransferase; ANA – antinuclear antibody; ASMA – antismooth muscle antibody; * n=34; ** n=38.
patients with and without ASMA. There were no significant intergroup differences with respect to age, sex, liver function, ANA positive rate, IgG levels, type of disease presentation, or grade of severity, except HLA-DR4 (Table 2).

Discussion

This is the first study to show that seropositivity and titer of ASMA were associated with relapse after treatment withdrawal or during maintenance therapy in type 1 AIH patients who reached remission once after medication. There were no similar results for ANA. Although ANA and ASMA are the most common markers for type 1 AIH, the etiological role of these autoantibodies has still not been elucidated. Some studies have shown the relationship between seropositivity of autoantibodies and biochemical activity of AIH. In a longitudinal study on childhood AIH, Gregorio et al. reported that ASMA and anti-LKM1 titers were associated with biochemical disease activity [15]. Moreover, a recent, larger cohort study reported that ASMA titers during treatment were significantly associated with histological and biochemical activity of AIH, but ANA titers were not [16]. Considering these results from previous studies and our present study, ASMA might be an important marker for disease activity associated with relapse of type 1 AIH.

Several studies demonstrated that relapse occurred in 25–30% of Japanese AIH patients on tapered schedules or after drug withdrawal [6,7,17]. Although suppression of relapse is important to improve prognosis of AIH, risk factors for relapse before initiation of treatment are not fully understood. Other than ASMA, only onset age differed significantly between relapsed and non-relapsed patients in our study. It was also with other autoimmune diseases did not differ significantly between the 2 groups.

Fifty-two patients underwent needle biopsy of the liver. There were no patients with advanced fibrosis in the relapsed group. Forty-five patients received prednisolone (PSL)-based treatment, and 8 were treated with ursodeoxycholic acid (UDCA) monotherapy (300–900 mg/day). UDCA monotherapy tended to be applied to elderly patients with low-grade histological and biochemical activity, or patients with comorbidity such as diabetes mellitus and osteoporosis. Relapse was not seen in patients treated with UDCA monotherapy. In the PSL-based treatment group, there was no significant differences between patients with and without relapse with respect to initial dose (39.3 vs. 34.0 mg), maintenance dose (3.2 vs. 4.0 mg), dose reduction rate (1.5 vs. 1.4 mg/week), withdrawal rate (42.9 vs. 20.0%), or time to remission (3.7 vs. 3.4 weeks).

To investigate the influence of autoantibody titers on relapse, we analyzed the correlation between relapse rate and titer of ASMA and ANA. Relapse rate increased with titer of ASMA, while titer of ANA did not correlate with relapse rate (Figure 1).

To clarify the usefulness of ASMA measurement, the positive predictive value (PV+) and the negative predictive value (PV−) for relapse were analyzed. When the cut-off value of ASMA titer was set at 1: 40, PV+ and PV− were 0.46 and 1.0, respectively, and if set at 1: 160, PV+ and PV− were 0.67 and 0.93, respectively.

We also investigated the characteristic differences between patients with and without ASMA. There were no significant

![Figure 1](image-url)

**Figure 1.** Relapse rates according to titers of ASMA and ANA. Bar graph (A) shows 34 patients who had ASMA checked and (B) shows 53 patients who had ANA checked. (A) Cases with an ASMA titer of 1: 160 or higher had significantly higher relapse rates than those with a titer of <1: 80 or negative (P=0.0005). (B) There was no association between relapse rates and ANA titers.

ASA – anti-smooth muscle antibody; ANA – antinuclear antibody.
reported that patients aged <45 years had an increased risk of relapse compared with elderly patients [18]. Al-Chalabi et al. indicated that there were no significant differences between patients presenting at age >60 years and <60 years with respect to mode of onset, other clinical signs at presentation, biochemical parameters, types or titers of autoantibodies, incidence of histological cirrhosis, response to therapy, and prognosis. They speculated that disease severity or activity of AIH might be related to immunological factors more than age per se [19]. In terms of treatment method, there were no differences between relapsed and non-relapsed patients in terms of initial dose, maintenance dose, and reduction rate of PSL in our study. The rate of PSL withdrawal and the time to remission in the relapsed group were also comparable to those

| Characteristic                        | ASMA +ve (n=13) | ASMA –ve (n=21) | P     |
|--------------------------------------|-----------------|-----------------|-------|
| Age (years)                          | 55.5±8.7        | 60.6±9.9        | 0.1360|
| Female                               | 13 (100)        | 17 (81.0)       | 0.0939|
| Body mass index (kg/m²)              | 23.8±4.0        | 22.0±3.9        | 0.2329|
| Platelet (*10⁹/mm³)                  | 20.2±4.4        | 19.1±7.5        | 0.6318|
| Albumin (g/dL)                       | 3.9±0.4         | 3.7±0.6         | 0.2059|
| Total bilirubin (mg/dL)              | 3.6±3.3         | 4.0±4.6         | 0.8605|
| AST (IU/L)                           | 415.8±361.8     | 447.0±505.3     | 0.8480|
| ALT (IU/L)                           | 620.6±521.4     | 458.0±558.3     | 0.4049|
| γ-glutamyltransferase (IU/L)         | 221.9±134.8     | 241.1±187.5     | 0.7503|
| Alkaline phosphatase (IU/L)          | 555.0±292.0     | 491.4±198.4     | 0.4544|
| Prothrombin activity (%)             | 91.5±18.9       | 81.8±16.4       | 0.1298|
| IgG (mg/dL)                          | 1989.5±508.0    | 2072.5±637.4    | 0.6941|
| ANA positive                         | 10 (76.9)       | 20 (95.2)       | 0.1072|
| HLA-DR4 positive*                    | 10/10 (100)     | 7/17 (41.2)     | 0.0022|
| Revised IAIHG score                  | 16.2±2.6        | 14.2±2.7        | 0.0474|
| Definite diagnosis                   | 9 (69.2)        | 8 (38.1)        | 0.0776|
| Severity (%)                         | 1 (7.7)         | 1 (4.8)         | 0.7242|
| Liver histology                      | 5 (38.5)        | 5 (23.8)        | 0.0568|
| Fibrosis stage F3 or F4              | 0 (0)           | 5 (23.8)        | 0.0568|
| Acute onset                          | 4 (30.8)        | 3 (14.3)        | 0.1276|
| Concomitant autoimmune disease       | 0 (0)           | 5 (23.8)        | 0.0568|
| Treatment                            | 10 (76.9)       | 17 (81.0)       | 0.7777|
| With steroid (predonisolone)         | 26.9±18.0       | 30.0±17.4       | 0.6313|
| Initial dose (mg)                    | 4.7±8.3         | 2.8±3.4         | 0.3656|
| Withdrawal                           | 3 (30.0)        | 5 (29.4)        | 0.9742|
| Reduction rate until ALT normalization (mg/week) | 1.7±1.6 | 1.6±1.5         | 0.8639|
| Duration to remission (weeks)        | 4.6±3.1         | 6.4±6.1         | 0.4193|

Results are expressed as the mean ± standard deviation or number (%). Statistical differences were analysed by t-test or χ² test. AST – aspartate aminotransferase; ALT – alanine aminotransferase; ANA – antinuclear antibody; ASMA – antismooth muscle antibody; * n=27.
in the non-relapsed group. Our results strongly suggest that ASMA could be an independent predictor for relapse during treatment or after withdrawal, because ASMA seropositivity and its titers had no association with factors such as age or corticosteroid treatment procedure (Table 2). In the present study, HLA-DR4 frequency was significantly higher in patients with ASMA. In terms of HLA phenotype, HLA-DR3 was reported to be associated with vigorous immune response [20]. On the other hand, HLA-DR4 was considered to have nothing to do with prognosis in a Japanese study [14]. We could not determine why the HLA-DR4-positive rate was higher in patients with ASMA in this study.

One major limitation was that our study was carried out in a small number of patients, and the data on ASMA, HLA, and histological findings were not available for all patients because it was a retrospective study. To confirm our results, prospective studies in a larger cohort are needed.

Conclusions

Our study suggests that ASMA positivity and its titer might have some association with refractory AIH pathogenesis, although its accuracy is not sufficient because of small sample size and retrospective nature.

Conflicts of interest

None.

References:

1. Miyake Y, Iwasaki Y, Terada R et al: Persistent normalization of serum alanine aminotransferase levels improves the prognosis of type 1 autoimmune hepatitis. J Hepatol, 2005; 43: 951–57
2. Czaja AJ: Rapidity of treatment response and outcome in type 1 autoimmune hepatitis. J Hepatol, 2009; 51: 161–67
3. Abe M, Mashiba T, Zeniya M et al: Present status of autoimmune hepatitis in Japan: a nationwide survey. J Gastroenterol 2011; 46: 1136–41.
4. Montano-Loza AJ, Carpenter HA, Czaja AJ: Consequences of treatment withdrawal in type 1 autoimmune hepatitis. Liver Int, 2007; 27: 507–15
5. Montano-Loza AJ, Carpenter HA, Czaja AJ: Improving the end point of corticosteroid therapy. Am J Gastroenterol, 2007; 102: 1005–12
6. Takahashi A, Ohira H, Abe K et al: Rapid corticosteroid tapering: Important risk factor for type 1 autoimmune hepatitis relapse in Japan. Hepatol Res, 2015; 45: 638–44
7. Yokokawa J, Kanno Y, Saito H et al: Risk factors associated with relapse of type 1 autoimmune hepatitis in Japan. Hepatol Res, 2011; 41: 641–46
8. Czaja AJ, Manns MP: The validity and importance of subtypes in autoimmune hepatitis: A point of view. Am J Gastroenterol, 1995; 90: 1206–11
9. Toda G, Zeniya M, Watanabe F et al: Present status of autoimmune hepatitis in Japan – correlating the characteristics with international criteria in an area with a high rate of HCV infection. J Hepatol, 1997; 26: 1207–12
10. Alvarez F, Berg PA, Bianchi FB et al: International Autoimmune Hepatitis Group Report: Review of criteria for diagnosis of autoimmune hepatitis. J Hepatol, 1999; 31: 920–38
11. Kaneko A, Tatsumi T, Yakushijin T et al: Present status of steroid administration to patients with autoimmune hepatitis and factors associated with relapse. Kanzo, 2015; 56: 507–17
12. Miyake Y, Iwasaki Y, Kobashi H et al: Autoimmune hepatitis with acute presentation in Japan. Dig Liver Dis, 2010; 42: 51–54
13. Onji M, Zeniya M, Yamamoto K, Tshbouchi H: Autoimmune hepatitis: Diagnosis and treatment guide in Japan, 2013. Hepatol Res, 2014; 44: 368–70
14. Desmet VJ, Gerber M, Hoofnagle JH et al: Classification of chronic hepatitis: Diagnosis, grading and staging. Hepatology, 1994; 19: 1513–20
15. Gregorio GV, McFarlane B, Bracken P et al: Organ and non-organ specific autoantibodies titres and IgG levels as markers of disease activity: A longitudinal study in childhood autoimmune liver disease. Autoimmunity, 2002; 35: 515–19
16. Couto CA, Bittencourt PL, Porta G et al: Antismooth muscle and antilactin antibodies are indirect markers of histological and biochemical activity of autoimmune hepatitis. Hepatology, 2014; 59: 592–600
17. Yoshizawa K, Matsumoto A, Ichijo T et al: Long-term outcome of Japanese patients with type 1 autoimmune hepatitis. Hepatology, 2012; 55: 668–76
18. van Gerven NM, Verwer BI, Witte BI et al: Relapse is almost universal after withdrawal of immunosuppressive medication in patients with autoimmune hepatitis in remission. J Hepatol, 2013; 58: 141–47
19. Al-Chalabi T, Boccato S, Portmann BC et al: Autoimmune hepatitis in the elderly. A systematic retrospective analysis of a large group of consecutive patients with definite AIH followed at a tertiary referral centre. J Hepatol, 2006; 45: 575–83
20. Czaja AJ, Carpenter HA: Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly. Hepatology, 2006; 43: 332–38